


Reticuline Datasheet

4th Edition (Revised in July, 2016)**[Product Information]****Name:** Reticuline**Catalog No.:** CFN98767**Cas No.:** 485-19-8**Purity:** >98%**M.F:** C₁₉H₂₃NO₄**M.W:** 329.40**Physical Description:** Powder

Synonyms: (S)-1,2,3,4-tetrahydro-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methylisoquinolin-7-ol; (1S)-1-[(3-hydroxy-4-methoxy-phenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; (S)-Reticuline; 2-Methoxy-5-[[[(1S)-2-methyl-6-methoxy-7-hydroxy-1,2,3,4-tetrahydroisoquinoline]-1-ylmethyl]phenol.

[Intended Use]

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

[Source]The root of *Thalictrum foliolosum*.

[Biological Activity or Inhibitors]

Reticuline is a key compound in the biosynthetic pathway for isoquinoline alkaloids in plants, which include morphine, codeine and berberine..^[1]

L-DOPA and reticuline exposure increases ganglionic morphine levels invivo and in vitro.^[2]

Reticuline possesses potent central nervous system depressant action, it (50-100 mg/kg i.p.) can produce alteration of behaviour pattern, prolongation of pentobarbital-induced sleep, reduction in motor coordination and D-amphetamine-induced hypermotility and suppression of the conditioned avoidance response. ^[3]

(S)-Reticuline can elicit vasorelaxation probably due to the blockade of the L-type voltage-dependent Ca(2+) current in rat aorta, the effect may contribute to the potential cardioprotective efficacy of (S)-reticuline.^[4]

[Solvent]

Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

[HPLC Method]^[5]

HPLC-MS

Mobile phase: 0.1%TFA in water- Meathnol, gradient eiution;

Flow rate: 1.0 ml/min;

Column temperature: Room Temperature;

Ion source temperature: 200 °C;

Detector voltage:1.5 kV;

CDL voltage: 15 V.

[Storage]

2-8°C, Protected from air and light, refrigerate or freeze.

[References]

- [1] Fujii N, Inui T, Iwasa K, *et al.* *Transgenic Res.*, 2007, 16(3):363-75.
- [2] Zhu W, Mantione K J, Shen L, *et al.* *Medical Science Monitor International Medical Journal of Experimental & Clinical Research*, 2005, 11(5):MS1-5.
- [3] Morais L C S L, Barbosa-Filho J M, Almeida R N. *J.Ethnopharmacol.*, 1998, 62(1):57-61.
- [4] Medeiros M A A, Nunes X P, Barbosa-Filho J M, *et al.* *N.-S. Arch. Pharmacol.*, 2009, 379(2):115-25.
- [5] Kim T J, Seo E Y, Yu S J, *et al.* *Korean Journal of Pharmacognosy*, 2012, 43(1):16-21.

[Contact]

Address:

S5-3 Building, No. 111, Dongfeng Rd.,
Wuhan Economic and Technological Development Zone,
Wuhan, Hubei 430056,
China

Email: info@chemfaces.com

Tel: +86-27-84237783

Fax: +86-27-84254680

Web: www.chemfaces.com

Tech Support: service@chemfaces.com